Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Constellation Pharmaceuticals Inc (CNST) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Constellation Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1434418.
Total stock buying since 2018: $88,473,871.
Total stock sales since 2018: $49,031,967.
Total stock option exercises since 2018: $3,202,246.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2021 | 0 | $0 | 48,983 | $1,766,581 | 43,970 | $292,543 |
| 2020 | 83,348 | $1,873,856 | 172,476 | $7,271,747 | 154,856 | $1,341,200 |
| 2019 | 5,035,293 | $63,599,990 | 1,371,401 | $39,993,639 | 244,008 | $1,480,983 |
| 2018 | 1,533,335 | $23,000,025 | 0 | $0 | 15,884 | $87,520 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2021-03 | 0 | $0 | 0 | $0 | 14,987 | $0 |
| 2021-02 | 0 | $0 | 31,780 | $1,182,333 | 11,780 | $94,709 |
| 2021-01 | 0 | $0 | 17,203 | $584,248 | 17,203 | $197,834 |
| 2020-12 | 0 | $0 | 9,740 | $341,574 | 5,720 | $40,640 |
| 2020-06 | 0 | $0 | 589 | $22,109 | 589 | $4,476 |
| 2020-05 | 0 | $0 | 107,238 | $5,007,786 | 93,638 | $743,072 |
| 2020-04 | 0 | $0 | 10,207 | $357,277 | 10,207 | $102,262 |
| 2020-03 | 83,348 | $1,873,856 | 617 | $19,777 | 617 | $5,404 |
| 2020-02 | 0 | $0 | 44,085 | $1,523,224 | 44,085 | $445,346 |
| 2019-12 | 800,000 | $27,600,000 | 0 | $0 | 0 | $0 |
| 2019-11 | 0 | $0 | 1,355,904 | $39,761,032 | 235,778 | $1,434,106 |
| 2019-10 | 4,235,293 | $35,999,990 | 15,497 | $232,607 | 8,230 | $46,877 |
| 2018-12 | 0 | $0 | 0 | $0 | 15,884 | $87,520 |
| 2018-07 | 1,533,335 | $23,000,025 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-03-04 | Goldsmith Mark A | Option Ex | 14,987 | .00 | 0 |
| 2021-02-22 | Reeve Emma (Chief Financial Officer) | Sale | 6,260 | 37.60 | 235,376 |
| 2021-02-22 | Reeve Emma (Chief Financial Officer) | Option Ex | 6,260 | 8.04 | 50,330 |
| 2021-02-19 | Reeve Emma (Chief Financial Officer) | Sale | 4,010 | 37.71 | 151,217 |
| 2021-02-19 | Reeve Emma (Chief Financial Officer) | Option Ex | 4,010 | 8.04 | 32,240 |
| 2021-02-18 | Reeve Emma (Chief Financial Officer) | Sale | 1,100 | 37.59 | 41,343 |
| 2021-02-18 | Reeve Emma (Chief Financial Officer) | Option Ex | 1,100 | 8.04 | 8,843 |
| 2021-02-17 | Reeve Emma (Chief Financial Officer) | Sale | 410 | 37.56 | 15,397 |
| 2021-02-17 | Reeve Emma (Chief Financial Officer) | Option Ex | 410 | 8.04 | 3,296 |
| 2021-02-17 | Kutzkey Tim (10% Owner) | Sale | 10,000 | 36.95 | 369,500 |
| 2021-02-17 | Svennilson Peter (10% Owner) | Sale | 10,000 | 36.95 | 369,500 |
| 2021-01-19 | Valentine Karen (See Remarks) | Sale | 17,203 | 33.96 | 584,248 |
| 2021-01-19 | Valentine Karen (See Remarks) | Option Ex | 17,203 | 11.50 | 197,834 |
| 2020-12-21 | Reeve Emma (Chief Financial Officer) | Sale | 5,720 | 35.11 | 200,806 |
| 2020-12-21 | Reeve Emma (Chief Financial Officer) | Option Ex | 5,720 | 7.11 | 40,640 |
| 2020-12-21 | Goldsmith Mark A | Sale | 4,020 | 35.02 | 140,768 |
| 2020-06-08 | Reeve Emma (Chief Financial Officer) | Sale | 589 | 37.54 | 22,109 |
| 2020-06-08 | Reeve Emma (Chief Financial Officer) | Option Ex | 589 | 7.60 | 4,476 |
| 2020-05-12 | Audia James E | Sale | 6,100 | 50.10 | 305,622 |
| 2020-05-12 | Raythatha Jigar (See Remarks) | Sale | 9,209 | 50.17 | 461,978 |
| 2020-05-12 | Raythatha Jigar (See Remarks) | Option Ex | 9,209 | 5.51 | 50,741 |
| 2020-05-12 | Senderowicz Adrian (Chief Medical Officer) | Sale | 9,357 | 50.17 | 469,487 |
| 2020-05-12 | Senderowicz Adrian (Chief Medical Officer) | Option Ex | 9,357 | 5.51 | 51,557 |
| 2020-05-12 | Goldsmith Mark A | Sale | 4,225 | 50.05 | 211,473 |
| 2020-05-12 | Goldsmith Mark A | Option Ex | 4,225 | 6.88 | 29,080 |
| 2020-05-11 | Raythatha Jigar (See Remarks) | Sale | 26 | 50.00 | 1,300 |
| 2020-05-11 | Raythatha Jigar (See Remarks) | Option Ex | 26 | 5.51 | 143 |
| 2020-05-11 | Reeve Emma (Chief Financial Officer) | Sale | 16,062 | 49.53 | 795,631 |
| 2020-05-11 | Reeve Emma (Chief Financial Officer) | Option Ex | 16,062 | 8.62 | 138,422 |
| 2020-05-11 | Goldsmith Mark A | Sale | 100 | 50.00 | 5,000 |
| 2020-05-11 | Goldsmith Mark A | Option Ex | 100 | 1.55 | 155 |
| 2020-05-08 | Reeve Emma (Chief Financial Officer) | Sale | 12,741 | 49.53 | 631,061 |
| 2020-05-08 | Reeve Emma (Chief Financial Officer) | Option Ex | 12,741 | 9.77 | 124,479 |
| 2020-05-06 | Trojer Patrick (Chief Scientific Officer) | Sale | 10,000 | 45.16 | 451,550 |
| 2020-05-06 | Trojer Patrick (Chief Scientific Officer) | Option Ex | 10,000 | 6.61 | 66,100 |
| 2020-05-06 | Audia James E | Sale | 7,500 | 45.15 | 338,602 |
| 2020-05-06 | Valentine Karen (See Remarks) | Sale | 12,566 | 40.10 | 503,896 |
| 2020-05-06 | Valentine Karen (See Remarks) | Option Ex | 12,566 | 10.13 | 127,293 |
| 2020-05-06 | Goldsmith Mark A | Sale | 11,463 | 45.06 | 516,545 |
| 2020-05-06 | Goldsmith Mark A | Option Ex | 11,463 | 6.88 | 78,899 |
| 2020-05-05 | Valentine Karen (See Remarks) | Sale | 4,744 | 40.01 | 189,816 |
| 2020-05-05 | Valentine Karen (See Remarks) | Option Ex | 4,744 | 11.50 | 54,556 |
| 2020-05-05 | Goldsmith Mark A | Sale | 3,145 | 40.01 | 125,825 |
| 2020-05-05 | Goldsmith Mark A | Option Ex | 3,145 | 6.88 | 21,647 |
| 2020-04-27 | Valentine Karen (See Remarks) | Sale | 400 | 40.13 | 16,052 |
| 2020-04-27 | Valentine Karen (See Remarks) | Option Ex | 400 | 11.50 | 4,600 |
| 2020-04-27 | Goldsmith Mark A | Sale | 400 | 40.12 | 16,049 |
| 2020-04-27 | Goldsmith Mark A | Option Ex | 400 | 1.55 | 620 |
| 2020-04-20 | Valentine Karen (See Remarks) | Sale | 789 | 33.65 | 26,549 |
| 2020-04-20 | Valentine Karen (See Remarks) | Option Ex | 789 | 11.50 | 9,073 |
| 2020-04-17 | Reeve Emma (Chief Financial Officer) | Sale | 760 | 35.29 | 26,819 |
| 2020-04-17 | Reeve Emma (Chief Financial Officer) | Option Ex | 760 | 6.61 | 5,023 |
| 2020-04-17 | Valentine Karen (See Remarks) | Sale | 2,300 | 35.19 | 80,939 |
| 2020-04-17 | Valentine Karen (See Remarks) | Option Ex | 2,300 | 11.50 | 26,450 |
| 2020-04-16 | Valentine Karen (See Remarks) | Sale | 2,998 | 33.69 | 100,999 |
| 2020-04-16 | Valentine Karen (See Remarks) | Option Ex | 2,998 | 11.50 | 34,477 |
| 2020-04-14 | Reeve Emma (Chief Financial Officer) | Sale | 1,225 | 35.20 | 43,122 |
| 2020-04-14 | Reeve Emma (Chief Financial Officer) | Option Ex | 1,225 | 8.76 | 10,731 |
| 2020-04-09 | Reeve Emma (Chief Financial Officer) | Sale | 700 | 35.02 | 24,512 |
| 2020-04-09 | Reeve Emma (Chief Financial Officer) | Option Ex | 700 | 8.18 | 5,726 |
| 2020-04-09 | Valentine Karen (See Remarks) | Sale | 635 | 35.02 | 22,236 |
| 2020-04-09 | Valentine Karen (See Remarks) | Option Ex | 635 | 8.76 | 5,562 |
| 2020-03-20 | Column Group Iii Gp, Lp (Other) | Buy | 5,539 | 23.15 | 128,227 |
| 2020-03-20 | Svennilson Peter (Other) | Buy | 5,539 | 23.15 | 128,227 |
| 2020-03-19 | Column Group Iii Gp, Lp (Other) | Buy | 36,135 | 22.38 | 808,701 |
| 2020-03-19 | Svennilson Peter (Other) | Buy | 36,135 | 22.38 | 808,701 |
| 2020-03-09 | Valentine Karen (See Remarks) | Sale | 617 | 32.05 | 19,777 |
| 2020-03-09 | Valentine Karen (See Remarks) | Option Ex | 617 | 8.76 | 5,404 |
| 2020-02-13 | Reeve Emma (Chief Financial Officer) | Sale | 5,521 | 35.05 | 193,538 |
| 2020-02-13 | Reeve Emma (Chief Financial Officer) | Option Ex | 5,521 | 8.04 | 44,388 |
| 2020-02-13 | Valentine Karen (See Remarks) | Sale | 4,473 | 35.07 | 156,859 |
| 2020-02-13 | Valentine Karen (See Remarks) | Option Ex | 4,473 | 10.13 | 45,311 |
| 2020-02-12 | Reeve Emma (Chief Financial Officer) | Sale | 1,103 | 35.02 | 38,623 |
| 2020-02-12 | Reeve Emma (Chief Financial Officer) | Option Ex | 1,103 | 8.04 | 8,868 |
| 2020-02-12 | Valentine Karen (See Remarks) | Sale | 1,500 | 35.02 | 52,527 |
| 2020-02-12 | Valentine Karen (See Remarks) | Option Ex | 1,500 | 11.50 | 17,250 |
| 2020-02-11 | Reeve Emma (Chief Financial Officer) | Sale | 8,642 | 35.04 | 302,815 |
| 2020-02-11 | Reeve Emma (Chief Financial Officer) | Option Ex | 8,642 | 7.82 | 67,580 |
| 2020-02-11 | Valentine Karen (See Remarks) | Sale | 8,550 | 35.03 | 299,506 |
| 2020-02-11 | Valentine Karen (See Remarks) | Option Ex | 8,550 | 11.50 | 98,325 |
| 2020-02-10 | Reeve Emma (Chief Financial Officer) | Sale | 200 | 35.00 | 7,000 |
| 2020-02-10 | Reeve Emma (Chief Financial Officer) | Option Ex | 200 | 7.60 | 1,520 |
| 2020-02-10 | Valentine Karen (See Remarks) | Sale | 14,096 | 33.51 | 472,356 |
| 2020-02-10 | Valentine Karen (See Remarks) | Option Ex | 14,096 | 11.50 | 162,104 |
| 2019-12-13 | Shah Nimish P (10% Owner) | Buy | 400,000 | 34.50 | 13,800,000 |
| 2019-12-13 | Evnin Anthony B (Director) | Buy | 400,000 | 34.50 | 13,800,000 |
| 2019-11-12 | Regents Of The University Of California | Sale | 12,800 | 32.77 | 419,456 |
| 2019-11-08 | Regents Of The University Of California | Sale | 1,074,316 | 30.34 | 32,600,119 |
| 2019-11-06 | Trojer Patrick (Chief Scientific Officer) | Sale | 46,142 | 25.07 | 1,157,010 |
| 2019-11-06 | Trojer Patrick (Chief Scientific Officer) | Option Ex | 37,920 | 6.28 | 238,137 |
| 2019-11-06 | Audia James E | Sale | 22,500 | 18.41 | 414,337 |
| 2019-11-06 | Raythatha Jigar (See Remarks) | Sale | 102,750 | 28.45 | 2,923,545 |
| 2019-11-06 | Raythatha Jigar (See Remarks) | Option Ex | 102,750 | 5.51 | 566,152 |
| 2019-11-06 | Reeve Emma (Chief Financial Officer) | Sale | 65,626 | 21.73 | 1,426,052 |
| 2019-11-06 | Reeve Emma (Chief Financial Officer) | Option Ex | 65,626 | 7.11 | 466,272 |
| 2019-11-06 | Senderowicz Adrian (Chief Medical Officer) | Sale | 27,232 | 27.61 | 751,902 |
| 2019-11-06 | Senderowicz Adrian (Chief Medical Officer) | Option Ex | 27,232 | 5.51 | 150,048 |
| 2019-11-05 | Trojer Patrick (Chief Scientific Officer) | Sale | 1,150 | 15.01 | 17,255 |
| 2019-11-05 | Trojer Patrick (Chief Scientific Officer) | Option Ex | 1,150 | 5.51 | 6,336 |
| 2019-11-05 | Audia James E | Sale | 2,288 | 15.01 | 34,352 |
| 2019-11-05 | Reeve Emma (Chief Financial Officer) | Sale | 1,000 | 15.50 | 15,504 |
| 2019-11-05 | Reeve Emma (Chief Financial Officer) | Option Ex | 1,000 | 6.61 | 6,610 |
| 2019-11-04 | Trojer Patrick (Chief Scientific Officer) | Sale | 100 | 15.00 | 1,500 |
| 2019-11-04 | Trojer Patrick (Chief Scientific Officer) | Option Ex | 100 | 5.51 | 551 |
| 2019-10-23 | Trojer Patrick (Chief Scientific Officer) | Sale | 300 | 15.20 | 4,559 |
| 2019-10-23 | Trojer Patrick (Chief Scientific Officer) | Option Ex | 300 | 5.51 | 1,653 |
| 2019-10-23 | Audia James E | Sale | 200 | 15.14 | 3,029 |
| 2019-10-22 | Trojer Patrick (Chief Scientific Officer) | Sale | 9,985 | 15.00 | 149,804 |
| 2019-10-22 | Trojer Patrick (Chief Scientific Officer) | Option Ex | 7,930 | 5.70 | 45,224 |
| 2019-10-22 | Audia James E | Sale | 5,012 | 15.01 | 75,215 |
| 2019-10-03 | Svennilson Peter (10% Owner) | Buy | 1,411,764 | 8.50 | 11,999,994 |
| 2019-10-03 | Evnin Anthony B (Director) | Buy | 2,823,529 | 8.50 | 23,999,996 |
| 2018-12-13 | Senderowicz Adrian (Chief Medical Officer) | Option Ex | 15,884 | 5.51 | 87,520 |
| 2018-07-23 | Casdin Venture Opportunities Fund Gp, Llc (10% Owner) | Buy | 266,667 | 15.00 | 4,000,005 |
| 2018-07-23 | Alexandria Venture Investments, Llc | Buy | 66,667 | 15.00 | 1,000,005 |
| 2018-07-23 | Orbimed Capital Gp Vi Llc (10% Owner) | Buy | 200,000 | 15.00 | 3,000,000 |
| 2018-07-23 | Deerfield Special Situations Fund, L.p. | Buy | 200,000 | 15.00 | 3,000,000 |
| 2018-07-23 | Evnin Anthony B (Director) | Buy | 133,334 | 15.00 | 2,000,010 |
| 2018-07-23 | Starr Kevin P (10% Owner) | Buy | 266,667 | 15.00 | 4,000,005 |
| 2018-07-23 | Tepper Robert I (Director) | Buy | 266,667 | 15.00 | 4,000,005 |
| 2018-07-23 | Regents Of The University Of California (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
Insider trading activities including stock purchases, stock sales, and option exercises of CNST listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Constellation Pharmaceuticals Inc (symbol CNST, CIK number 1434418) see the Securities and Exchange Commission (SEC) website.